Review: taking Xalatan and Alphagan p together


Summary

Drug interactions are reported among people who take Xalatan and Alphagan p together. This review analyzes the effectiveness and drug interactions between Xalatan and Alphagan p. It is created by eHealthMe based on reports of 1,932 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Xalatan

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. (latest outcomes from Xalatan 18,874 users)

Alphagan P

Alphagan p has active ingredients of brimonidine tartrate. It is often used in glaucoma. (latest outcomes from Alphagan p 1,882 users)

On Sep, 19, 2016

1,932 people who take Xalatan, Alphagan P are studied.


Number of reports submitted per year:

Xalatan and Alphagan p drug interactions.

Drug effectiveness over time:

Xalatan:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 3 people)
  • 2 - 5 years: 0.0% - (0 of 4 people)
  • 5 - 10 years: 20.0% - (1 of 5 people)
  • 10+ years: 33.0% - (1 of 3 people)
  • not specified: 0.0% - (0 of 0 people)
Alphagan P:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 3 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 2 people)
  • 10+ years: 25.0% - (1 of 4 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Xalatan:
  • female: 20.0% - (2 of 10 people)
  • male: 14.0% - (1 of 7 people)
Alphagan P:
  • female: 12.0% - (1 of 8 people)
  • male: 12.0% - (1 of 8 people)

Drug effectiveness by age:

Xalatan:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 25.0% - (1 of 4 people)
  • 60+: 0.0% - (0 of 10 people)
Alphagan P:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 25.0% - (1 of 4 people)
  • 60+: 0.0% - (0 of 8 people)

Most common drug interactions over time *:

< 1 month:
  • vision blurred
  • eye irritation
  • eye pain
  • drug ineffective
  • ocular hyperaemia
  • anxiety
  • dizziness
  • eyelid oedema
  • hypersensitivity
  • macular degeneration
1 - 6 months:
  • pancytopenia
  • pyrexia
  • bone marrow failure
  • inflammation
  • cough
  • tonsillitis
  • dyspnoea
  • nasal congestion
  • abnormal dreams
  • eye irritation
6 - 12 months:
  • cough
  • neutropenia
  • thrombocytopenia
  • dyspnoea
  • nasal congestion
  • abnormal dreams
  • blood alkaline phosphatase increased
  • blood creatinine increased
  • general physical health deterioration
  • herpes zoster
1 - 2 years:
  • nasal congestion
  • cough
  • dyspnoea
  • intraocular pressure increased
  • pain
  • abnormal dreams
  • growth of eyelashes
  • tinnitus
  • drug ineffective
  • ocular hyperaemia
2 - 5 years:
  • depression
  • eye irritation
  • ocular hyperaemia
  • drug hypersensitivity
  • eye disorder
  • intraocular pressure increased
  • tinnitus
  • abnormal dreams
  • amnesia
  • arrhythmia
5 - 10 years:
  • bradycardia
  • malaise
  • cataract
  • drug ineffective
  • cardiac disorder
  • dizziness
  • dyspnoea
  • fatigue
  • gastrointestinal haemorrhage
  • intraocular pressure increased
10+ years:
  • eyelid margin crusting
  • pressure sore
  • asthenia
  • blepharitis
  • blister
  • corneal disorder
  • eye colour change
  • eye irritation
  • eyelash discolouration
  • eyelid cyst
not specified:
  • intraocular pressure increased
  • drug ineffective
  • glaucoma
  • dyspnoea
  • visual acuity reduced
  • eye irritation
  • fatigue
  • pain
  • dizziness
  • fall

Most common drug interactions by gender *:

female:
  • drug ineffective
  • dyspnoea
  • visual acuity reduced
  • fatigue
  • intraocular pressure increased
  • glaucoma
  • pain
  • eye irritation
  • dizziness
  • asthenia
male:
  • intraocular pressure increased
  • glaucoma
  • eye irritation
  • drug ineffective
  • visual acuity reduced
  • dyspnoea
  • ocular hyperaemia
  • pain
  • cardiac failure congestive
  • dizziness

Most common drug interactions by age *:

0-1:
  • apnoea
  • bradycardia neonatal
  • cyanosis neonatal
  • depressed level of consciousness
  • developmental delay
  • feeding problem in newborn
  • hypotension
  • hypothermia
  • hypotonia neonatal
  • iris disorder
2-9:
  • injection site pain
10-19:
  • antibody test abnormal
  • coombs test positive
  • glaucoma aggravated
  • haemoglobin decreased
  • immunodeficiency
20-29:
  • drug ineffective
  • vitreous haemorrhage
  • corneal oedema
  • intraocular pressure increased
  • vision blurred
  • blood pressure decreased
  • dyspnoea
  • feeling abnormal
  • hypertension
  • retinal tear
30-39:
  • blood alkaline phosphatase increased
  • blood creatinine increased
  • general physical health deterioration
  • herpes zoster
  • neutropenia
  • pneumonia
  • pubis fracture
  • renal impairment
  • sepsis
  • thrombocytopenia
40-49:
  • intraocular pressure increased
  • eye irritation
  • visual acuity reduced
  • ocular hyperaemia
  • blindness unilateral
  • cataract
  • drug ineffective
  • gastrointestinal haemorrhage
  • intestinal obstruction
  • pneumonia
50-59:
  • dyspnoea
  • pain
  • glaucoma
  • visual acuity reduced
  • pneumonia
  • nausea
  • vomiting
  • anaemia
  • fatigue
  • fall
60+:
  • intraocular pressure increased
  • drug ineffective
  • eye irritation
  • visual acuity reduced
  • fatigue
  • asthenia
  • glaucoma
  • vision blurred
  • dizziness
  • nausea

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Xalatan and Alphagan p?

You may be interested in these reviews

More reviews for: Xalatan, Alphagan p

On eHealthMe, Xalatan (latanoprost) is often used to treat glaucoma. Alphagan p (brimonidine tartrate) is often used to treat glaucoma. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.